17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as
17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), work in different ways to stop
cancer cells from dividing so they stop growing or die.
PURPOSE: This phase I trial is studying the side effects and best dose of 17-DMAG in treating
patients with an advanced solid tumor or lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
National Institutes of Health Clinical Center (CC)